Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Marshall Islands Healthcare Brief.
Press releases published on October 15, 2025
DETERA Therapeutics Wins the Ipsen Golden Ticket 2025
PRESS RELEASE DETERA Therapeutics Wins the Ipsen Golden Ticket 2025 A strategic recognition of the biotech’s potential by a leading pharmaceutical group Paris, October 15th 2025 — DETERA Therapeutics, a biotechnology company specializing in disruptive …
Olympia Pharmaceuticals and Wesley Pharmaceuticals Co-Founder Naomi Loomis Establishes $10,000 Scholarship for The Ohio State University’s College of Pharmacy
ORLANDO, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Naomi Loomis, an alumnus of The Ohio State University College of Pharmacy and co-founder of Olympia Pharmaceuticals and Wesley Pharmaceuticals, has announced the establishment of The John Paul Dillow …
PathAI Expands AISight Dx with v2.17 Release: Presentation Queues for Tumor Boards, Consult Workflows and Voice-Enabled Reporting
BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- PathAI, the global leader in AI-powered pathology, today announced AISight® Dx1 v2.17, introducing three new capabilities to its cloud-based digital pathology image management system. Built to support both lab …
Lice Clinics of America Opens New Clinic in Elmhurst, IL
Elmhurst, IL, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Families in the western Chicago suburbs have a new reason to feel relieved when head lice strike. Lice Clinics of America, the world’s largest network of professional lice treatment centers, is proud to …
Aeroflow Health Expands Access to Lactation Services for DC Medicaid Members
ASHEVILLE, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support the delivery of medical products and services, today announced it is offering lactation care services …
Agenda Announced for 2026 MDA Clinical & Scientific Conference Featuring Leading Speakers Dedicated to Groundbreaking Research and Clinical Achievements in Neuromuscular Disease
New York, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the agenda including tracks and chairs for the 2026 MDA Clinical …
Vivian Health Launches AI Assistant for Recruiters to Transform Healthcare Hiring
SAN FRANCISCO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Vivian Health, the largest online marketplace for healthcare talent with over 2.5 million registered users, today announced the launch of its AI Assistant for recruiting. The debut marks Vivian’s evolution …
InformedDNA and Know Your Lemons Foundation® Expand Access to Early Detection and Genetic Counseling for Breast Cancer
Partnership combines expertise in oncology, patient education and precision medicine with personalized screening recommendations for those at various risks for breast cancer Extends Know Your Lemons’ mission to provide breast cancer education and guidance …
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
MELBOURNE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100 million with Hexstone Capital LLC ("Hexstone"), a family …
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total …
MMI Enrolls First Patient in Landmark U.S. Clinical Study Advancing Robotic Microsurgery
JACKSONVILLE, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced the first patient …
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health …
Clover Health’s 2026 Medicare Advantage Plans Champion Affordability and Choice
JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, …
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 annual endovascular procedures …
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025
PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market …
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive …
Chiesi Announces FDA Acceptance of New Drug Application for its Triple Combination Inhaler for the Maintenance Treatment of Asthma
Asthma remains a significant health burden in the U.S., with more than 60% of adults continuing to experience frequent symptoms despite the availability of many treatments.1 Chiesi’s single inhaler triple therapy (beclomethasone dipropionate/formoterol …
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year. New, potentially best-in-class ADC is targeting a tumor selective marker …
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing …